SJN314 / Samjin Pharma - LARVOL DELTA

Samjin Pharmaceutical applies for domestic Phase 1 clinical trials of novel inflammation and immunology drug candidate SJN314 (BioNews) - "The clinical study was designed with the potential for ‘proof-of-concept based on early human data’ (demonstration of efficacy in early human clinical trials), a critical criterion for global pharmaceutical companies when evaluating potential technology transfers. Samjin Pharm emphasized that this trial represents a strategically structured development approach, intended to enable prompt initiation of global partnering discussions immediately following the completion of Phase 1 clinical trial."

New P1 trial • Immunology • Inflammation